Study of three drugs for advanced CML and Ph+ AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of three drugs (decitabine, lisaftoclax, and olverembatinib) for people with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute myeloid leukemia who have not responded to or could not tolerate previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You have a specific type of leukemia: advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute myeloid leukemia.
- You have tried at least one prior targeted therapy (BCR::ABL1 inhibitor) and it did not work or you could not tolerate it.
- Your overall health status allows for daily activities with some help (ECOG performance status 0-3).
- Your liver, kidneys, heart, and pancreas are working well enough based on blood tests.
- You cannot have had a previous allergic reaction to any of the study drugs.
- You cannot have had acute pancreatitis in the last year or have chronic pancreatitis.
- You cannot have serious, uncontrolled heart problems or a recent heart attack or stroke.
- You must be able to take pills by mouth.
- If you are able to become pregnant, you must use effective birth control during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four drugs (FLAG-IDA, venetoclax, asciminib, and possibly blinatumomab) for people with chronic myeloid leukemia or acute myeloid leukemia that carry a specific genetic change called the Philadelphia chromosome. The goal is to see if this combination can help people achieve remission and improve survival.
This trial tests a combination of three medicines—azacitidine, venetoclax, and gilteritinib—in people with specific gene changes (FLT3 mutations) in leukemia and related bone marrow diseases that have come back or are hard to treat. The goal is to see if this drug combination can control the disease and improve outcomes.
This trial tests a combination of three drugs (olverembatinib, venetoclax, and azacitidine) for people with a fast-growing form of chronic myeloid leukemia (CML) called blast phase. The goal is to see if this treatment can help control the leukemia when it has moved to a more aggressive stage.
This trial tests a new combination of three drugs (a third-generation TKI, azacitidine, and a Bcl-2 inhibitor) for people with chronic myeloid leukemia that has progressed to a more advanced phase (myeloid blast phase). The goal is to see if this combination is safe and effective.
This trial tests new treatment options for people whose acute myeloid leukemia (AML) has either not responded to standard therapy or returned. It aims to find better ways to help those who need new options.
This early-phase trial tests lisaftoclax, alone or with other medicines, in people whose acute leukemia has returned or did not respond to prior treatment. It aims to find out how well the treatment works and how safe it is, especially for patients who may not be able to take standard chemotherapy.
Hear when a new Advanced Chronic Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.